Paul A Lacaze

List of Publications by Year
in descending order

79 papers	2,141 citations	331642 21 h-index	265191 42 g-index
94 all docs	94 docs citations	94 times ranked	4419 citing authors

#	Article	IF	Citations
1	The Transcription Factor STAT-1 Couples Macrophage Synthesis of 25-Hydroxycholesterol to the Interferon Antiviral Response. Immunity, 2013, 38, 106-118.	14.3	327
2	Host Defense against Viral Infection Involves Interferon Mediated Down-Regulation of Sterol Biosynthesis. PLoS Biology, 2011, 9, e1000598.	5.6	241
3	Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nature Cell Biology, 2010, 12, 235-246.	10.3	178
4	Identification of a human neonatal immune-metabolic network associated with bacterial infection. Nature Communications, 2014, 5, 4649.	12.8	112
5	Blood DNA methylation as a potential biomarker of dementia: A systematic review. Alzheimer's and Dementia, 2018, 14, 81-103.	0.8	77
6	Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genetics in Medicine, 2019, 21, 1958-1968.	2.4	63
7	A logic-based diagram of signalling pathways central to macrophage activation. BMC Systems Biology, 2008, 2, 36.	3.0	56
8	Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies. Frontiers in Public Health, 2018, 6, 181.	2.7	55
9	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. Heart Lung and Circulation, 2021, 30, 324-349.	0.4	51
10	ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. Nature Communications, 2015, 6, 6548.	12.8	49
11	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nature Communications, 2020, 11, 435.	12.8	47
12	Public Involvement in Global Genomics Research: A Scoping Review. Frontiers in Public Health, 2019, 7, 79.	2.7	41
13	Reversible Inhibition of Murine Cytomegalovirus Replication by Gamma Interferon (IFN-Î³) in Primary Macrophages Involves a Primed Type I IFN-Signaling Subnetwork for Full Establishment of an Immediate-Early Antiviral State. Journal of Virology, 2011, 85, 10286-10299.	3.4	40
14	Construction of a large scale integrated map of macrophage pathogen recognition and effector systems. BMC Systems Biology, 2010, 4, 63.	3.0	35
15	Rare disease registries: a call to action. Internal Medicine Journal, 2017, 47, 1075-1079.	0.8	33
16	Whole blood gene expression profiling of neonates with confirmed bacterial sepsis. Genomics Data, 2015, 3, 41-48.	1.3	32
17	Genetic discrimination by Australian insurance companies: a survey of consumer experiences. European Journal of Human Genetics, 2020, 28, 108-113.	2.8	29
18	Temporal Profiling of the Coding and Noncoding Murine Cytomegalovirus Transcriptomes. Journal of Virology, 2011, 85, 6065-6076.	3.4	28

#	Article	IF	Citations
19	The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. European Journal of Human Genetics, 2019, 27, 308-316.	2.8	28
20	Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry, 2020, 10, 37.	4.8	24
21	Combined genome-wide expression profiling and targeted RNA interference in primary mouse macrophages reveals perturbation of transcriptional networks associated with interferon signalling. BMC Genomics, 2009, 10, 372.	2.8	22
22	Genetics and Insurance in Australia: Concerns around a Self-Regulated Industry. Public Health Genomics, 2017, 20, 247-256.	1.0	22
23	Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12056.	2.4	22
24	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. European Heart Journal, 2022, 43, 3243-3254.	2.2	22
25	Genetic resilience to Alzheimer's disease in APOE Îµ4 homozygotes: A systematic review. Alzheimer's and Dementia, 2019, 15, 1612-1623.	0.8	21
26	Loss of Y and clonal hematopoiesis in bloodâ€"two sides of the same coin?. Leukemia, 2022, 36, 889-891.	7.2	21
27	Should Australia Ban the Use of Genetic Test Results in Life Insurance?. Frontiers in Public Health, 2017, 5, 330.	2.7	20
28	Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. Genetics in Medicine, 2020, 22, 1883-1886.	2.4	20
29	Implementation of public health genomics in Pakistan. European Journal of Human Genetics, 2019, 27, 1485-1492.	2.8	19
30	Monitoring the genetic testing and life insurance moratorium in Australia: a national research project. Medical Journal of Australia, 2021, 214, 157.	1.7	17
31	CD200 Receptor Restriction of Myeloid Cell Responses Antagonizes Antiviral Immunity and Facilitates Cytomegalovirus Persistence within Mucosal Tissue. PLoS Pathogens, 2015, 11, e1004641.	4.7	16
32	DNA methylation analysis of candidate genes associated with dementia in peripheral blood. Epigenomics, 2020, 12, 2109-2123.	2.1	16
33	Effect of APOE and a polygenic risk score on incident dementia and cognitive decline in a healthy older population. Aging Cell, 2021, 20, e13384.	6.7	16
34	Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. Stroke, 2021, 52, 2882-2891.	2.0	15
35	Genetic testing and insurance in Australia. Australian Journal of General Practice, 2019, 48, 96-99.	0.8	15
36	The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies. Internal Medicine Journal, 2017, 47, 461-463.	0.8	14

#	Article	IF	Citations
37	Regulation of Internet-based Genetic Testing: Challenges for Australia and Other Jurisdictions. Frontiers in Public Health, 2018, 6, 24.	2.7	14
38	Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals. Journal of the National Cancer Institute, 2021, 113, 1379-1385.	6.3	14
39	Genetics, Insurance and Professional Practice: Survey of the Australasian Clinical Genetics Workforce. Frontiers in Public Health, 2018, 6, 333.	2.7	13
40	Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. Clinical Pharmacology and Therapeutics, 2020, 108, 1289-1298.	4.7	13
41	Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003429.	3.6	13
42	Quantitative assessment of human whole blood RNA as a potential biomarker for infectious disease. Analyst, The, 2007, 132, 1200.	3.5	12
43	Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer. Cancers, 2021, 13, 1495.	3.7	12
44	Study protocol: the Australian genetics and life insurance moratoriumâ€"monitoring the effectiveness and response (A-GLIMMER) project. BMC Medical Ethics, 2021, 22, 63.	2.4	12
45	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. Npj Genomic Medicine, 2021, 6, 51.	3.8	11
46	Pathogenic variants in the healthy elderly: unique ethical and practical challenges. Journal of Medical Ethics, 2017, 43, 714-722.	1.8	10
47	Baseline characteristics and age-related macular degeneration in participants of the â€œASPirin in Reducing Events in the Elderlyâ€•(ASPREE)-AMD trial. Contemporary Clinical Trials Communications, 2020, 20, 100667.	1.1	10
48	Population DNA screening for medically actionable disease risk in adults. Medical Journal of Australia, 2022, 216, 278-280.	1.7	10
49	Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing. Npj Breast Cancer, 2021, 7, 153.	5.2	10
50	Genetic testing in dementiaâ€A medical genetics perspective. International Journal of Geriatric Psychiatry, 2021, 36, 1158-1170.	2.7	9
51	Genomic Risk Score for Advanced Osteoarthritis in Older Adults. Arthritis and Rheumatology, 2022, 74, 1480-1487.	5.6	9
52	Familial Hypercholesterolemia in a Healthy Elderly Population. Circulation Genomic and Precision Medicine, 2020, 13, e002938.	3.6	8
53	Disclosing genetic information to family members without consent: Five Australian case studies. European Journal of Medical Genetics, 2020, 63, 104035.	1.3	7
54	Impact of direct-to-consumer genetic testing on Australian clinical genetics services. European Journal of Medical Genetics, 2020, 63, 103968.	1.3	7

#	Article	IF	Citations
55	Polygenic score modifies risk for Alzheimer's disease in APOE Îµ4 homozygotes at phenotypic extremes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12226.	2.4	7
56	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. Cancers, 2021, 13, 5815.	3.7	7
57	Response to Veenstra et al.. Genetics in Medicine, 2019, 21, 2842-2843.	2.4	6
58	Healthcare System-Funded Preventive Genomic Screening: Challenges for Australia and Other Single-Payer Systems. Public Health Genomics, 2019, 22, 140-144.	1.0	6
59	Prevalence and disease predisposition of p.A91V perforin in an aged population of European ancestry. Blood, 2020, 135, 582-584.	1.4	6
60	Genomic Risk Prediction for Breast Cancer in Older Women. Cancers, 2021, 13, 3533.	3.7	6
61	A step forward, but still inadequate: Australian health professionalsâ€™ views on the genetics and life insurance moratorium. Journal of Medical Genetics, 2022, 59, 817-826.	3.2	6
62	Involving people affected by a rare condition in shaping future genomic research. Research Involvement and Engagement, 2021, 7, 14.	2.9	5
63	Involving elderly research participants in the co-design of a future multi-generational cohort study. Research Involvement and Engagement, 2021, 7, 23.	2.9	5
64	Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. Cancer Prevention Research, 2022, 15, 447-454.	1.5	5
65	A polygenic risk score predicts mosaic loss of chromosome Y in circulating blood cells. Cell and Bioscience, 2021, 11, 205.	4.8	5
66	The Dangers of Direct-to-Consumer GeneticÂTestingÂfor Alzheimerâ€™s Disease. Journal of Bioethical Inquiry, 2017, 14, 585-587.	1.5	4
67	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. Internal Medicine Journal, 2021, 51, 769-779.	0.8	4
68	Penetrance and the Healthy Elderly. Genetic Testing and Molecular Biomarkers, 2017, 21, 637-640.	0.7	3
69	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. American Journal of Preventive Cardiology, 2021, 6, 100151.	3.0	3
70	Recovery of natural killer cell cytotoxicity in a A91V perforinhomozygous patient following severe haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2020, 190, 458-461.	2.5	2
71	Population Genomic Screening of All Young Adults in a Health-Care System: A Cost-Effectiveness Analysis. Obstetrical and Gynecological Survey, 2020, 75, 91-93.	0.4	2
72	Editorial: Public Health Genomics. Frontiers in Public Health, 2019, 7, 142.	2.7	1

#	Article	IF	Citations
73	Ethical and practical implications of returning genetic research results: two Australian case studies. Medical Journal of Australia, 2021, 214, 259.	1.7	1
74	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. Open Heart, 2021, 8, e001710.	2.3	1
75	The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population. Thrombosis and Haemostasis, 2022, 122, 1130-1138.	3.4	1
76	Co-designing genomics research with a large group of donor-conceived siblings. Research Involvement and Engagement, 2021, 7, 89.	2.9	1
77	Using whole-genome sequencing to characterize clinically significant blood groups among healthy older Australians. Blood Advances, 2022, 6, 4593-4604.	5.2	1
78	Whole-genome sequencing analysis of clozapine-induced myocarditis. Pharmacogenomics Journal, 2022, 22, 173-179.	2.0	1
79	Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. Cancer Prevention Research, 2022, 15, 509-519.	1.5	1